A phase I study of irinotecan, bevacizumab and biweekly TAS-102 in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin

ABSTRACT: Interventions: TAS-102 25-35 (mg/m2) day1-5 CPT-11 150-180 (mg/m2) day 1 Bevacizumab 5 (mg/kg) day 1 every 2 weeks Primary outcome(s): Part1(dose-escalation): DLT between first 2 cycles Part2(expansion): the incidence of febrile neutropenia Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2635113 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR